Tesamorelin Research for Growth Hormone Optimization
An evidence-based overview of research examining Tesamorelin in the context of growth hormone optimization. This page synthesizes findings from peer-reviewed literature.
Research Summary
Tesamorelin is a GHRH-receptor agonist that stimulates pituitary GH secretion and raises IGF-1. The 2007 pivotal trial reported an 81.0% IGF-1 rise versus a 5.0% fall on placebo at week 26. This biomarker finding does not demonstrate safer GH replacement or a general "optimization" indication. The EGRIFTA WR label warns that sustained IGF-1 elevation has unknown effects and calls for monitoring.
Referenced Studies
Click any PMID to view the full study on PubMed.
Important Disclaimer
This page summarizes research findings and does not constitute medical advice. Always consult a healthcare provider before making health decisions.